LYRIC BIO

📍 San Francisco, United States🗓 Founded 2024👥 12 employees💰 Last funded Jul 2025
Pharmaceutical Manufacturing🌐 lyricbio.com
Website LinkedIn
Lyric Bio, Inc. is on a mission to reshape the global supply of life-saving medicines with its next-generation biomanufacturing platform. Every year, thousands of patients with immune deficiencies and neurological disorders rely on intravenous immunoglobulin (IvIg), but supply remains critically limited—often falling short of growing needs. The global IvIg market is already valued at over $20 billion and is projected to see strong growth as both diagnosis rates and clinical indications rise. Yet, traditional plasma-derived processes cannot keep pace, leaving patients and clinicians facing persistent shortages. Lyric Bio stands at the forefront of this market opportunity, unlocking scalable, efficient production technology to break through the bottlenecks that have long constrained access. For patients, Lyric Bio’s innovation means hope—offering the promise of consistent, reliable access to high-quality therapies. By reimagining how essential biologics like IvIg are made, Lyric Bio is delivering groundbreaking technology that will enable first in vitro production other donor derived complex therapeutics such as stem cells and red blood cells.
4
Total investors
4
Early stage
0
Mid stage
0
Late stage
2024
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
3
Singapore
1
Frequently asked questions
Who invested in LYRIC BIO?
LYRIC BIO has 4 investors on record on gritt.io, including 4 early-stage backers.
When did LYRIC BIO last raise funding?
The most recent investment in LYRIC BIO recorded on gritt.io was in July 2025.
When was LYRIC BIO founded?
LYRIC BIO was founded in 2024.
What industry is LYRIC BIO in?
LYRIC BIO operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is LYRIC BIO based?
LYRIC BIO is headquartered in San Francisco, United States.